Sanofi CEO Paul Hud­son’s lat­est M&A gam­bit adds new eczema drug in $1.5B buy­out. And he’s steer­ing back in­to a mar­ket mael­strom

Around the same time that Sanofi CEO Paul Hud­son was en­gi­neer­ing a $3.7 bil­lion buy­out of Prin­cip­ia to add a late-stage mul­ti­ple scle­ro­sis drug to the pipeline last Au­gust, the team at Kymab was post­ing up­beat re­marks about its mid-stage da­ta on their ri­val OX40L drug for atopic der­mati­tis. Now Hud­son has come back in to ink a $1.45 bil­lion deal to buy Kymab out and add that to the late-stage im­muno-in­flam­ma­tion pipeline as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER